TY - JOUR T1 - Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic diseases JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 595 LP - 597 DO - 10.1136/annrheumdis-2021-221688 VL - 81 IS - 4 AU - Tai-Ju Lee AU - Cheng-Hsun Lu AU - Song-Chou Hsieh Y1 - 2022/04/01 UR - http://ard.bmj.com/content/81/4/595.abstract N2 - The SARS-CoV-2 vaccination is one of the major strategies against the COVID-19 pandemic. The novel platforms of vaccines were developed to replace the time-consuming traditional vaccine manufacturing process, but this worldwide campaign raises new safety issues. A new panel of adverse events was recently reported at nation-wide registry levels.1 However, the information is very limited in patients with rheumatic diseases, who potentially have increased risks of adverse events due to immune dysregulation or concomitant therapies.We retrospectively collected the diseases, immunomodulators, types of vaccines and adverse events from patients receiving at least one dose of primary SARS-CoV-2 vaccine at rheumatology clinics of a tertiary referral centre in Taiwan. The data were analysed using the Fisher’s exact test for dichotomous variables and Wilcoxon rank sum test for continuous variables. Between July 2021 and September 2021, 265 patients were enrolled, including patients with Sjogren’s syndrome (n=49), rheumatoid arthritis (n=34), systemic lupus erythematosus (n=33), spondyloarthritis (n=21) and other rheumatic diseases (online supplemental table S1). Eighty-nine (33.7%) patients received ChAdOx1 nCoV-19 (AZD1222) vaccine (AstraZeneca/Oxford) and 176 (66.3%) received mRNA-1273 (Moderna) vaccines. The median (IQR) ages were 50 years (39, 60) in AZD1222 and 58 years … ER -